Le Lézard
Classified in: Environment, Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

CB Therapeutics Revolutionizes Color and Antioxidant Production: Precision Fermentation Sets New Standard for Cost-Efficiency and Sustainability


CB Therapeutics (the "Company"), a frontrunner in biotechnology and precision fermentation, announces a monumental stride towards sustainability with the introduction of natural food and product colors, coupled with potent antioxidants. This innovative leap not only transforms coloration and nutrition but also sets a new benchmark for environmental responsibility in the food and industrial sectors.

Harnessing the transformative potential of precision fermentation, CB Therapeutics unveils a vibrant palette of natural colors, including striking orange from carrots (?-carotene), deep purple from beets (betalains), bold red from tomatoes (lycopene), sunny yellow from marigolds (lutein), and more. The synergy of these hues offers an extensive array of colors, catering to diverse consumer demands and industrial applications.

Beyond their aesthetic allure, these natural molecules serve as vital antioxidants and nutrients, fortifying cells against harmful free radicals and bolstering overall health. The adoption of CB Therapeutics' innovative solutions not only elevates product quality but also reinforces a commitment to consumer well-being and environmental stewardship, emphasized Sher Ali Butt, Co-Founder and CEO of CB Therapeutics.

Jacob Vogan, Co-Founder and CSO of CB Therapeutics, added that "in stark contrast to conventional methods, which often entail exorbitant costs, lengthy processes, and yield significant environmental repercussions, precision fermentation offers a sustainable and efficient alternative. By utilizing precision fermentation, CB Therapeutics significantly reduces carbon emissions, with estimates suggesting a reduction of metric tons of CO2 annually compared to traditional color production methods."

CB Therapeutics is now looking to collaborate with partners in need of these sustainable colors. Interested companies should reach out to our CEO at [email protected].

About CB Therapeutics

CB Therapeutics' expertise in synthetic genomics and bio-engineering has significantly advanced its proprietary production platform of microorganisms, enzymes, and production processes. After more than nine years of research and development, the CB Therapeutics team can produce a broad range of phytochemicals faster, utilizing fewer resources, at greater yields, and with more purity, consistency, and efficiency than competing platforms. CB Therapeutics operates from their new 16,000 sq. ft. facility in southern California.

Follow CB Therapeutics on Twitter: @CBTherapeutics
Follow CB Therapeutics on Instagram: @cb_thera


These press releases may also interest you

at 09:00
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, announced today the...

at 09:00
April 30, 2024 Philips AI-enabled diagnostic and experiential technologies help put patients at ease while empowering staff with faster, high-quality scans and increased diagnostic confidence Amsterdam, the Netherlands, and Miami, US ? Royal...

at 08:57
LGI Healthcare Solutions, a Canadian leader in healthcare IT, proudly announces the selection of its LGI Education (MedSIS 3C) solution to transform medical learner assessment processes and streamline administrative operations at the University of...

at 08:55
Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with...

at 08:55
RetiSpec, Inc., an innovator in AI-powered eye diagnostics for brain health, and Topcon Healthcare, Inc. a leading provider of medical devices and software solutions announced today that Topcon has invested in RetiSpec and the two companies are...

at 08:53
The FDA has been warning healthcare providers and the public about malfunctioning plastic syringes made in China since November 2023. The affected syringes are leaking, cracking, and breaking ? putting patients at risk of receiving incorrect doses of...



News published on and distributed by: